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To assess the efficacy of thoracic epidural anesthesia (TEA) with or without general anesthesia (GA) versus GA in
patients who underwent cardiac surgery, PubMed, Embase, the Cochrane online database, and Web of Science
were searched with the limit of randomized controlled trials (RCTs) relevant to ‘thoracic epidural anesthesia’ and
‘cardiac surgery’. Studies were identified and data were extracted by two reviewers independently. The quality of
included studies was also assessed according to the Cochrane handbook. Outcomes of mortality, cardiac and
respiratory functions, and treatment-associated complications were pooled and analyzed. The comprehensive search
yielded 2,230 citations, and 25 of them enrolling 3,062 participants were included according to the inclusion criteria.
Compared with GA alone, patients received TEA and GA showed reduced risks of death, myocardial infarction, and
stroke, though there were no significant differences (P > 0.05). With regard to treatment-related complications, the
pooled results for respiratory complications (risk ratio (RR), 0.69; 95% CI: 0.51, 0.91, P < 0.05), supraventricular arrhythmias
(RR, 0.61; 95% CI: 0.42, 0.87, P < 0.05), and pain (mean difference (MD), −1.27; 95% CI: −2.20, −0.35, P < 0.05) were 0.69,
0.61, and −1.27, respectively. TEA was also associated with significant reduction of stays in intensive care unit
(MD, −2.36; 95% CI: −4.20, −0.52, P < 0.05) and hospital (MD, −1.51; 95% CI: −3.03, 0.02, P > 0.05) and time to tracheal
extubation (MD, −2.06; 95% CI:−2.68, −1.45, P < 0.05). TEA could reduce the risk of complications such as
supraventricular arrhythmias, stays in hospital or intensive care unit, and time to tracheal extubation in patients
who experienced cardiac surgery.
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Introduction
The evolution of techniques and knowledge of anesthesiology
has resulted in decreased occurrence of surgery-related
complications and subsequently improved clinical out-
comes after surgery [1-3]. General anesthesia (GA) and
thoracic epidural anesthesia (TEA) have been introduced
in cardiac and pulmonary surgery for a long time [4]. It
is suggested that TEA could provide better outcomes
after operation than GA [5-7]. Indeed, lots of studies
have focused on this issue and reported that TEA was
associated with better outcomes and less operation-
related complications [8-10].* Correspondence: zhangshengsuomed@163.com
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unless otherwise stated.As TEA has the potential of perfect pain control and
high satisfaction within patients, it is a highly effective
procedure for relieving acute pain after operation or se-
vere trauma of the chest [11,12]. Studies also reveal that
TEA has the advantages of improving myocardial oxygen
balance, increasing coronary perfusion, and reducing
complications such as supraventricular arrhythmias after
surgery [13,14]. In addition, TEA may also reduce the
duration of tracheal intubation and stay in intensive care
unit and thus may save the patients with appropriate
cost-effectiveness [15,16]. However, the application of
TEA in clinical practice is more or less limited because
of its increased risk of adverse events such as epidural
hematoma or abscess, even spinal cord compression
[10,17]. Besides, required systemic anticoagulation during
cardiac surgery may promote the happening of epidural
hematoma relevant to the use of an epidural catheter [18].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study flow diagram.
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troversial. It is crucial to update the advantages and disad-
vantages of TEA in the treatment of patients who have
experienced surgery.
Patients (1,178) were identified in a previously pub-
lished meta-analysis and it showed that the risk of death
or myocardial infarction after cardiac surgery was similar
between patients treated with TEA versus GA, but TEA
treatment was associated with a less incidence of re-
spiratory complications and dysrhythmias than GA alone
[19]. However, since then, more randomized controlled
trials (RCTs) comparing the effect of TEA either in com-
bination with GA or alone versus GA alone have ap-
peared in the database [14,20].
In this meta-analysis, we aimed to address whether
TEA with or without GA in cardiac surgery could im-
prove the clinical outcomes such as mortality and reduce
cardiac, pulmonary, or neurological complications,
expecting to provide reliable evidence in determining
the risk-benefit ratio of TEA.
Methods
Data sources and search strategy
By combining well-selected synonyms for cardiac sur-
gery and epidural anesthesia, pertinent articles were re-
trieved by two reviewers comparing TEA with or
without GA versus GA alone from PubMed, Embase, the
Cochrane online library, Web of Science, with restric-
tions for English language and RCT type. The function
of ‘see related articles’ in PubMed was used to comple-
ment additional citations. In addition, if the full text was
not available, we contacted authors for a complete
manuscript. The detailed PubMed and Embase search
strategy was developed according to Vesna Svircevic
et al. [14] and can be obtained from Additional file 1.
Study selection
Studies identified from systematic searches of database
and literatures were initially reviewed at the title or ab-
stract level by two authors independently, and disagree-
ments were resolved by discussion or a third reviewer.
With regard to the rest references, we defined eligibility
criteria to further select related citations and these cri-
teria were as follows: the ages of patients should not be
less than 18; randomization was used to allocate patients
to treatment; studies containing the comparison of TEA
with or without GA versus GA alone, and no restriction
in dose and administration of GA; studies comparing
cardiac surgery with or without spinal anesthesia were
excluded; animal experimental researches, limited data
of interest in studies, and duplicate literatures were also
discarded. Studies with limited data were excluded and
one hundred percentage of agreement on included stud-
ies were tried to make.Data extraction and quality evaluation
The primary outcomes were mortality and myocardial
infarction, and the secondary outcomes were pulmonary
complications (pneumonia or limited function of respira-
tory), cardiac complications (supraventricular dysrhyth-
mias or other events), and neurological complications
(hematoma or abscess in epidural, transient ischaemic
attack and others). Information relevant to the above
outcomes as well as baseline data were abstracted by
two well-trained reviewers independently. Other data
such as duration of mechanical ventilation, hospital
stay, and indicators of heart function and injury were
also collected. As the mortality data in individual stud-
ies were reported at different times of follow-up, we de-
fined and measured the death rate at short-term and
long-term after operation.
The Cochrane Handbook for systematic reviews of in-
terventions (version 5.1) [21] was introduced to appraise
the internal validity of eligible studies and assess the risk
of bias of selection, allocation, performance, detection,
and reporting in each selected article. The whole evalu-
ation process was done by one reviewer and checked by
another investigator. If a consensus decision was en-
countered and this was not disappeared by discussion,
then the third author was involved in the final decision.
Data synthesis and analysis
The overall effect of TEA was assessed on the improve-
ment of primary and secondary outcomes based on the
data of included RCTs. The dichotomous variables in
Table 1 Baseline characteristics of included studies
First author Year Patients (n) Age (mean ± std) Sex(M/F) Surgery TEA medication
TEA ± GA GA TEA ± GA GA TEA ± GA GA
Bach 2002 13 13 60 ± 8 64 ± 7 11/2 17/10 ECABG Bupivacaine
Bakhtiary 2007 66 66 66 ± 8 64 ± 9 54/12 58/8 OCBG Ropivacaine and sufentanil
Barrington 2005 60 60 63 ± 9 62 ± 10 53/7 51/9 CABG Ropivacaine/fentanyl
Berendes 2003 36 37 61 ± 11 59 ± 12 11/26 9/27 ECABG Bupivacaine and sufentanil
Caputo 2009 36 38 63.8 ± 9.8 66.5 ± 9.3 32/4 34/4 OCBG Propofol and fentanyl
Caputo 2011 109 117 65.9 ± 8.8 65.5 ± 8.6 102/7 102/15 OCBG Bupivacaine
de Vries 2002 30 60 57 ± 11 60 ± 11 20/10 47/13 OPCABG Bupivacaine and sufentanil
Fillinger 2002 30 30 - - - - CABG Bupivacaine/ morphine
Hansdottir 2006 55 55 65 ± 10 68 ± 11 38/20 38/17 ECS Bupivacaine
Heijmans 2007 15 45 61 ± 10 - - - ECS Bupivacaine and remifentanil
Kendall 2004 10 20 66 ± 4.6 - 8/2 14/6 ECS Isoflurane and bupivacaine
Lagunilla 2006 25 25 66.08 ± 8.28 64.04 ± 10.15 22/3 22/3 ECS Ropivacaine/fentanyl
Lundstrom 2005 26 24 66 ± 15 63 ± 11 - - ECS Bupivacaine
Nygard 2004 79 84 - - - - CABG Bupivacaine
Onan 2011 15 15 58.5 ± 6.0 59.4 ± 9.3 14/1 13/2 CABG Bupivacaine
Priestley 2002 50 50 58 ± 10 60 ± 8 8/42 6/44 CABG Ropivacaine/fentanyl
Scott 2001 206 202 59.2 ± 8.94 58.8 ± 9.18 - - CABG Bupivacaine
Svircevic 2011 325 329 65 ± 10 64 ± 10 266/59 277/52 CABG
Kiliçkan 2006 40 40 61.1 ± 8.9 58.6 ± 13.1 16/4 17/3 CABG Bupivacaine/fentanyl
Royse 2003 37 39 64.2 ± 9.3 65.1 ± 10.8 30/7 30/9 CABG Ropivacaine/fentanyl
Sharma 2010 30 30 58.2 ± 8.0 58.0 ± 8.3 27/3 29/1 OPCABG Bupivacaine/fentanyl
Gurses 2013 32 32 62.8 ± 10.5 61.7 ± 8.8 8/24 10/22 CABG Fentanyl/ levobupivacaine
Rajakaruna 2013 109 117 65.9 ± 8.8 65.5 ± 8.6 102/7 102/15 OPCABG Bupivacaine
Jakobsen 2012 30 30 70.9 ± 4.6 71.6 ± 4.5 21/9 18/12 ECS Bupivacaine
Onan 2013 20 20 59.2 ± 9.6 58.1 ± 6.7 19/1 17/3 CABG Bupivacaine
Abbreviation: TEA thoracic epidural anesthesia, GA general anesthesia, ECABG elective arterial coronary bypass grafting, OCBG off-pump coronary bypass grafting,
CABG arterial coronary bypass grafting, OPCABG off-pump CABG surgery, ECS elective cardiac surgery.
Figure 2 Risk of bias of included studies based on the
authors’ judgement.
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a 95% confidence interval (CI) or odds ratio (OR) with a
95% CI. The review manager 5.2 software was used to
perform quantitative analysis. As ordinarily accepted, the
fixed effects model for pooled analysis was firstly used.
Heterogeneity across eligible studies was detected by
using the I2 statistic, which is a quantitative measure of
lack of consistency across studies. If an I2 statistic of
studies is between 0% to 50%, it is considered that low
heterogeneity exists within these studies, those with an
I2 statistic of 50% to 75% are considered to have mod-
erate heterogeneity, and if I2 statistic is larger than
75%, a high degree of heterogeneity are considered in
these trials [22]. Usually, it is considered that there is
no important heterogeneity if the value of I2 across the
studies is less than 50% [23]. When significant hetero-
geneity was detected, a random-effects model was used
for analysis. Subgroup or sensitivity analyses were ap-
plied if there was a necessity.Results
Search results
A total of 2,230 articles were initially identified by the
comprehensive search. One hundred and thirty five of
them were discarded as they were duplicative refer-
ences, and 1,903 of them were excluded after a careful
review of their titles or abstracts. The assessment of
Figure 3 Risk of bias summary.
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meet the eligibility criteria. For the remaining 35 arti-
cles, there were no experimental design in one study,
no outcome data (further detailed information could
not be obtained via contacting authors) in 5 articles,
and these citations were also excluded. Eventually,
twenty-five RCTs [24-49] were included and their data
were extracted and synthesized to evaluate the com-
bining effect of TEA on clinical outcomes. The detailed
process of study selection was illustrated in Figure 1
and the characteristics of eligible studies were pre-
sented in Table 1.
Risk of bias in included studies
We mainly assessed the risk of bias of selection, perform-
ance, detection, attrition, and reporting. Although we only
included randomized controlled trials, the selection bias
remained unclear due to the incomplete reporting of
randomization and allocation method. As illustrated in
Figures 2 and 3, the application of blinding was reported
in a few articles and the majority of the included studies
were with high risk of performance bias. With regard to
the bias of attrition and reporting, the risks were relatively
low. The funnel plot showed that there was no significant
publication bias (Figure 4).
Effects of interventions
Mortality Among the eligible studies, 12 of them pro-
vided the data of mortality. In these RCTs, the TEA
intervention was not associated with a significant im-
provement in mortality. Death in either TEA group or
GA group was infrequent. A total of 8 deaths were pre-
sented in TEA group and 10 events were reported in
GA group. At last, these studies enrolling 2,181 patients
were included for the combined analysis. As the mea-
sured heterogeneity was not significant, we selected
fixed-effects model to perform the analysis. As presented
in Figure 5, the application of TEA had an effect on re-
ducing the risk of death with an estimate RR of 0.89, butFigure 4 Funnel plot of included studies relevant to mortality.
Figure 5 A Forest plot for the comparison of epidural anesthesia versus control on the pooled endpoint death.
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in long term (RR, 0.89; 95% CI:0.42, 1.87. P > 0.05).
Myocardial infarction The pooled analysis of effect of
TEA on the myocardial infarction was performed using
the data from ten articles with 1,812 participants. A total
of 149 events were reported in the TEA intervention,
compared to the GA group with 153 events. As the
value of I2 was less than 20% and the value of Z was lar-
ger than 0.1, we did not find a significant heterogeneity.
Figure 6 shows the synthesized result and exhibits that
the TEA treatment was not sufficient to significantly
prevent the patients from suffering myocardial infarc-
tion, compared with GA alone (RR, 0.98; 95% CI:0.83,
1.15. P > 0.05). Sensitivity analysis did not show a signifi-
cant effect on the results.
Pain relief There were eight articles which reported the
effect of TEA on pain control, and most of them used
the visual analog scale (VAS) score to determine the de-
gree of pain. We used fixed-effects model to perform
this analysis and found that patients received TEAFigure 6 Meta-analysis of the effect of epidural anesthesia versus consuffered less pain than those of GA treatment (mean dif-
ference, −1.27; 95% CI: −2.20, −0.35, P < 0.05. Figure 7).Stays in hospital or intensive care unit A total of eight
studies provided information on stays in hospital or inten-
sive care unit; however, the duration of stay and terms of
reporting varied between studies, increasing the risk of in-
consistency. The pooled analysis exhibited that the use of
TEA significantly reduced the time spent in intensive care
unit (MD, −2.36; 95% CI: −4.20, −0.52, P < 0.05. Figure 8)
and hospital (MD, −1.51; 95% CI: −3.03, 0.02, P > 0.05.
Figure 9), indicating a relatively lower cost.Time to tracheal extubation The time to tracheal extu-
bation was reported in seven studies, and the reporting
term and unit of time were different among these trials.
By checking the value of I2, we found there was no
significant heterogeneity in studies. As illustrated by
Figure 10, compared to GA arm, TEA arm showed a
significant reduction of time to tracheal extubation
(MD, −2.06; 95% CI: −2.68, −1.45. P < 0.05).trol on the composite endpoint myocardial infarction.
Figure 7 Summarized comparison of epidural anesthesia versus control on the pain relief.
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tients from 12 RCTs were included in this pooled analysis,
and there were 293 events in the TEA group and 390
events in the GA group. The detection of heterogeneity
showed a low inconsistency across the studies and thus
the fixed-effects model was applied. The result of meta-
analysis indicated that there was no significant effect on
the prevention of supraventricular tachyarrhythmias by
adding TEA to GA (RR, 0.61; 95% CI: 0.42, 0.87, P < 0.05.
Figure 11).
Respiratory complications With regard to the respira-
tory complications, 10 studies with 1,867 patients reported
information on the incidence of events. The majority of
these complications appeared within 14 days after surgery.
A total of 92 events were reported in the TEA arm and
129 events were shown in the GA arm. The heterogeneity
among these trials was not significant (I2 = 48%, P = 0.05).
By using fixed-effects model, the results illustrated by
Figure 12 showed that TEA could significantly reduce
the prevalence of respiratory complications for patients
with cardiac surgery, compared with patients receiving GA
during operation (RR, 0.69; 95% CI: 0.51, 0.91, P < 0.05).
Neurologic events As TEA was reported with a higher
risk of incidence of epidural hematoma or abscess, we
planned to perform this analysis to determine this effect.
However, these events were not reported in all of the in-
cluded studies. Stroke was another rare complication
and only seven RCTs reported the data of this event,
making it difficult to fully reveal the effect of TEA on
the incidence of stroke. The TEA group had 7 events
and the GA group had 14 events. After evaluating theFigure 8 A Forest plot for the comparison of epidural anesthesia versheterogeneity of these studies (I2 = 0%, P > 0.05), we per-
formed this analysis and found that there was a lower
risk of stroke in patients receiving TEA and GA, com-
pared with those with GA alone (RR, 0.55; 95% CI: 0.24,
1.28, P > 0.05. Figure 13).
Discussion
This meta-analysis using combined data from several
RCTs determined that TEA with or without GA did not
show a benefit in reducing the rate of death or the risk
of myocardial infarction during perioperation, though
TEA with or without GA showed a significant effect on
reduction of risk of supraventricular tachyarrhythmias,
respiratory complications, and time to extubation. These
results suggested that TEA on the top of GA could pro-
vide additional benefits on clinical outcomes for patients
receiving cardiac surgery. The effect of TEA on lowering
the risk of mortality or myocardial infarction may be
underpowered due to the extremely low events in both
groups.
The methodological assessment of quality of included
trials suggests that the reliability of our study is moder-
ate and this is mainly due to the incomplete details of
biases of selection, blinding and attrition. Randomized
controlled trials are the optimal evidence for analyzing
effect of intervention, [50] and this kind of studies are
included in our meta-analysis. Though randomization
has been applied in these articles, allocation conceal-
ment, which is another kind of selection bias, is rarely
reported, resulting in a moderate risk of selection bias.
As for biases of performance and detection, the risk is
relatively high due to the unclear information about
blinding in each study, and this is the main cause of theus control on the outcome of stays in intensive care unit.
Figure 9 A Forest plot for the comparison of epidural anesthesia versus control on the stays in hospital.
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biases caused by incomplete outcome data or selective
reporting; however, these biases are associated with low
risk and have little effect on the overall heterogeneity.
Considering the imperfect quality of included trials, we
carefully give our recommendation on the finding of this
meta-analysis.
TEA is considered as the gold standard analgesic inter-
vention for major surgery [51]. TEA with or without GA
has the potential to provide sufficient pain control and
has been used in cardiac surgery for years. Mortality as a
severe result of cardiac surgery can be related to the
complicated procedures or perioperative injury or pain.
The activation of endocrine, neural, and metabolic path-
ways and inflammatory reactions all contribute to this
unfavorable event probably by damaging myocardium,
causing pain and other reasons [51]. Though cardiac
surgery may result in mortality, the incidence of mortal-
ity is very low. In our meta-analysis, by combining the
events in both TEA arm and GA arm, we found that the
rate was 0.8% (18 deaths/2,181 patients in total). The
pooled result suggested that the relief of pain was signifi-
cantly improved in the TEA arm, compared with GA
group. But this reduction of pain did not result in a
lower risk of mortality. This may be explained by the ex-
tremely low and varied reporting of mortality in in-
cluded studies.
Myocardial infarction is one of the most serious com-
plications related to surgery, making myocardium one of
the most important tissues needs protection from ische-
mia during surgeries [52]. Although there were different
definitions of myocardial infarction used in includedFigure 10 A Forest plot for the comparison of epidural anesthesia versstudies, most of them correctly defined this event by
employing biomarkers of myocardium and ECG examin-
ation. Myocyte necrosis/apoptosis is the main cause of
elevation of biomarkers after cardiac surgery; one study
[42] reported that TEA plus GA preserved cardiac func-
tion by reducing apoptosis and improving hemodynamic
function. However, the combined data in our study
showed that TEA and GA had a similar effect on lowering
the occurrence of myocardial infarction. One of the expla-
nations may be the direct myocardial injury from ven-
tricular venting, sewing needles or direct cardioversion or
manipulation of the heart, [52] which could not be simply
protected by TEA.
This meta-analysis also suggested that application of
TEA could save patients from suffering cardiac or pul-
monary or neurologic complications and reducing
duration of intubation and stays in intensive care unit or
hospital. These may contribute to a better cost-
effectiveness of TEA, despite its insufficient efficacy on
reducing mortality and myocardial infarction. Studies
have reported that TEA may improve myocardial oxygen
balance and reduce perioperative stress response [53,54].
We did find a benefit of TEA in controlling heart beats;
however, the stress response could not be assessed by
meta-analysis due to the limited information provided
by few studies.
There are a few similar meta-analysis published in re-
cent years [14,19,55]. Liu et al. [19] found that TEA was
associated with significant reduction of arrhythmias, pul-
monary complications, time to tracheal intubation, and
postoperative pain. Their meta-analysis failed to deter-
mine the beneficial effect of TEA on reducing risk ofus control on the composite endpoint time to tracheal extubation.
Figure 11 A meta-analysis of the comparison of epidural anesthesia versus control on the supraventricular tachyarrhythmias.
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Another meta-analysis published by Guay [55] suggested
that in patients operated on under GA, the addition of
TEA reduced the incidence of arrhythmia with an OR of
0.59, and the time to tracheal extubation was reduced by
3.9 h, stay of intensive care unit also reduced. In our
meta-analysis, we suggested that among patients who
experienced cardiac surgery treatment-related complica-
tions and consumption of time in hospital or intensive
care unit were reduced. Cardiac functions could be im-
proved by using TEA, although TEA could not reduce
the risk of death. Our result is consistent with previous
meta-analysis. Recently, Mehta Y pointed out that TEA
might decrease pulmonary, cardiovascular, or renal com-
plications, provide excellent analgesia, and allow early
extubation in high-risk cardiac surgical patients [56]. A
larger scale RCT should be done to further confirm this
point.
As drawbacks of meta-analysis are difficult to avoid,
there are also few limitations in this study, making our
findings less reliable. First, the application of TEA inFigure 12 A Forest plot for the comparison of epidural anesthesia verscardiac surgery is in a debate, and this study failed to de-
termine a significant reduction of mortality or myocar-
dial infarction in patients treating with TEA plus GA.
There is an urgent need for large number, multi-center,
randomized, blinded clinical trials which could provide
sufficient data on mortality or myocardial infarction or
stroke as well as epidural hematoma relevant to the
intervention of TEA. Second, although all of the in-
cluded studies were RCTs, the quality of them varied.
There was an obvious bias of selection because most of
them did not report the information of blinding. And
the time point of measuring and methods of detection
were not in accordance with each other. Third, some of
the studies have been published for several years, and
there are remarkable developments in procedures or
techniques after these years, and this may contribute to
a higher risk of heterogeneity when these studies were
included. Finally, there may be some publication bias in
this meta-analysis, which may exaggerate the difference
between TEA with or without GA and GA alone in the
cardiac surgery.us control on the composite endpoint respiratory complications.
Figure 13 A Forest plot for the comparison of epidural anesthesia versus control on the composite endpoint stroke.
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This meta-analysis suggests that the anesthetic regimen
of TEA is not sufficient to reduce the risk of mortality
or myocardial infarction after cardiac surgery; however,
TEA appears to benefit patients by lowering incidence of
respiratory complications, cardiac events, or neurologic
complications and reducing duration of postoperative
ventilation. Viewing the related risk of epidural
hematoma or abscess, the application of TEA should be
carefully considered in well-selected patients who are
going to undergo cardiac surgery, unless multi-center
RCTs with large number of participants are available
and their data could be powered to an outcome favoring
the application of TEA.Additional file
Additional file 1: Searching strategy. Databases.Abbreviations
CI: confidence interval; GA: general anesthesia; OR: odds ratio;
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